These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 15064752

  • 1. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
    Dhar A, Hu J, Reeves R, Resar LM, Colburn NH.
    Oncogene; 2004 May 27; 23(25):4466-76. PubMed ID: 15064752
    [Abstract] [Full Text] [Related]

  • 2. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
    Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH.
    Oncogene; 1998 Dec 31; 17(26):3493-8. PubMed ID: 10030673
    [Abstract] [Full Text] [Related]

  • 3. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
    Jansen AP, Colburn NH, Verma AK.
    Oncogene; 1999 Oct 14; 18(42):5806-13. PubMed ID: 10523861
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
    Li JJ, Dong Z, Dawson MI, Colburn NH.
    Cancer Res; 1996 Feb 01; 56(3):483-9. PubMed ID: 8564958
    [Abstract] [Full Text] [Related]

  • 5. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH.
    Oncogene; 1998 May 28; 16(21):2711-21. PubMed ID: 9652737
    [Abstract] [Full Text] [Related]

  • 6. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
    Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR, Young MR, Colburn NH.
    Cancer Res; 2007 Mar 15; 67(6):2430-8. PubMed ID: 17363560
    [Abstract] [Full Text] [Related]

  • 7. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
    Chun KS, Kim SH, Song YS, Surh YJ.
    Carcinogenesis; 2004 May 15; 25(5):713-22. PubMed ID: 14729583
    [Abstract] [Full Text] [Related]

  • 8. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model.
    Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT.
    Mol Cancer Res; 2003 Sep 15; 1(11):848-54. PubMed ID: 14517347
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
    Kim G, Khanal P, Lim SC, Yun HJ, Ahn SG, Ki SH, Choi HS.
    Carcinogenesis; 2013 Feb 15; 34(2):341-50. PubMed ID: 23125217
    [Abstract] [Full Text] [Related]

  • 10. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine.
    Fan M, Goodwin ME, Birrer MJ, Chambers TC.
    Cancer Res; 2001 Jun 01; 61(11):4450-8. PubMed ID: 11389075
    [Abstract] [Full Text] [Related]

  • 11. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response.
    Li JJ, Westergaard C, Ghosh P, Colburn NH.
    Cancer Res; 1997 Aug 15; 57(16):3569-76. PubMed ID: 9270030
    [Abstract] [Full Text] [Related]

  • 12. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.
    Chang PL, Cao M, Hicks P.
    Carcinogenesis; 2003 Nov 15; 24(11):1749-58. PubMed ID: 12919959
    [Abstract] [Full Text] [Related]

  • 13. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
    Suzukawa K, Colburn NH.
    Oncogene; 2002 Mar 28; 21(14):2181-90. PubMed ID: 11948401
    [Abstract] [Full Text] [Related]

  • 14. Organ-specific activation of activator protein-1 in transgenic mice by 12-o-tetradecanoylphorbol-13-acetate with different administration methods.
    Zhong S, Quealy JA, Bode AM, Nomura M, Kaji A, Ma WY, Dong Z.
    Cancer Res; 2001 May 15; 61(10):4084-91. PubMed ID: 11358830
    [Abstract] [Full Text] [Related]

  • 15. A JNK1/AP-1-dependent, COX-2 induction is implicated in 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation through regulating cell cycle progression.
    Zhang D, Li J, Song L, Ouyang W, Gao J, Huang C.
    Mol Cancer Res; 2008 Jan 15; 6(1):165-74. PubMed ID: 18234971
    [Abstract] [Full Text] [Related]

  • 16. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.
    Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn N.
    Proc Natl Acad Sci U S A; 1999 Aug 17; 96(17):9827-32. PubMed ID: 10449779
    [Abstract] [Full Text] [Related]

  • 17. Differentiation-associated genes regulated by TPA-induced c-Jun expression via a PKC/JNK pathway in KYSE450 cells.
    Yu X, Luo A, Zhou C, Ding F, Wu M, Zhan Q, Liu Z.
    Biochem Biophys Res Commun; 2006 Mar 31; 342(1):286-92. PubMed ID: 16480952
    [Abstract] [Full Text] [Related]

  • 18. Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.
    Kim JE, Son JE, Jang YJ, Lee DE, Kang NJ, Jung SK, Heo YS, Lee KW, Lee HJ.
    J Pharmacol Exp Ther; 2011 Sep 31; 338(3):1013-22. PubMed ID: 21705614
    [Abstract] [Full Text] [Related]

  • 19. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.
    Liu G, Bode A, Ma WY, Sang S, Ho CT, Dong Z.
    Cancer Res; 2001 Aug 01; 61(15):5749-56. PubMed ID: 11479211
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model.
    Zhao Y, Xue Y, Oberley TD, Kiningham KK, Lin SM, Yen HC, Majima H, Hines J, St Clair D.
    Cancer Res; 2001 Aug 15; 61(16):6082-8. PubMed ID: 11507057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.